Data from Bristol-Myers Squibb shows that Opdivo and Yervoy together and Opdivo by itself were better than Yervoy alone in giving those with untreated advanced melanoma a better chance to live.
The information came from the Checkmate-067 testing of Opdivo and Yervoy. Of those diagnosed with advanced melanoma who lived another two years, 64 percent took Opdivo and Yervoy, 59 percent took just Opdivo and 45 percent took Yervoy alone, according to an announcement.
Opdivo and Yervoy together reduced the patients' chances of dying by 45 percent, while those using just Opdivo saw their risk of death drop 37 percent when put up against those who used just Yervoy.
Opdivo and Yervoy together raised the percentage of those who had no sign of cancer from 12.1 percent to 17.2 percent compared to an 18-month follow-up. In that same breakdown against the 18-month follow-up, Opdivo by itself increased the percentage of those who had no sign of cancer from 9.8 percent to 14.9 percent, and Yervoy by itself from 2.2 percent to 4.4 percent.